Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) shares rose 7.4% during trading on Friday . The company traded as high as $20.17 and last traded at $20.15. Approximately 22,633 shares changed hands during trading, a decline of 89% from the average daily volume of 200,219 shares. The stock had previously closed at $18.76.
Analyst Upgrades and Downgrades
Separately, StockNews.com raised shares of Pulse Biosciences to a "sell" rating in a research report on Wednesday, November 27th.
Get Our Latest Analysis on PLSE
Pulse Biosciences Trading Up 5.3 %
The stock's 50-day moving average price is $17.59 and its 200 day moving average price is $16.23.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same quarter last year, the business earned ($0.19) EPS.
Institutional Trading of Pulse Biosciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in PLSE. Vanguard Group Inc. increased its stake in Pulse Biosciences by 28.8% in the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company's stock valued at $7,379,000 after acquiring an additional 189,227 shares during the period. Price T Rowe Associates Inc. MD bought a new stake in Pulse Biosciences in the first quarter valued at about $88,000. Cetera Advisors LLC bought a new stake in Pulse Biosciences in the first quarter valued at about $109,000. Westside Investment Management Inc. increased its stake in Pulse Biosciences by 97.8% in the second quarter. Westside Investment Management Inc. now owns 63,600 shares of the company's stock valued at $712,000 after acquiring an additional 31,440 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in Pulse Biosciences by 23.4% in the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company's stock valued at $570,000 after acquiring an additional 9,639 shares during the period. Institutional investors own 76.95% of the company's stock.
About Pulse Biosciences
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Featured Articles
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
